The newly identified p53-related gene, p73, encodes a nuclear transcription factor. Unlike p53, p73 has various isoforms with different NH 2 -and COOH-terminal tails. p73a with the longest COOH-terminal extension is most abundantly expressed in many tissues and cells among those splicing isoforms of p73 and the COOH-terminal region appears to have an autoregulatory function. To isolate and characterize the cellular protein(s) that interacts with the unique COOH-terminal region of p73a, we employed a yeast two-hybrid screen with a human fetal brain and 293 cell cDNA libraries. We identified the receptor for activated C kinase (RACK1) as a new member of p73a-binding proteins. The interaction was confirmed by coimmunoprecipitation experiments, whereas RACK1 did not interact with p53 or p73b. Ectopic overexpression of RACK1 in SAOS-2 cells reduced the p73a-mediated transcription from the p53/ p73-responsive promoters, and inhibited the p73a-dependent apoptosis. On the other hand, the p53-dependent transcriptional activation as well as apoptosis was unaffected in the presence of RACK1. Furthermore, we found that pRB physically bound to RACK1, and repressed the RACK1-dependent inhibition of p73a. Taken together, our observations suggest that pRB diminishes the RACK1-mediated inhibition of p73a activity through the interaction with RACK1.
Introduction
The tumor suppressor p53 transactivates various p53-responsive target genes that are required for cell cycle arrest and/or apoptosis in response to cellular genotoxic stress such as DNA damage, hypoxia, and viral or oncogene activation (Oren, 1994; Ko and Prives, 1996; Levine, 1997; Giaccia and Kastan, 1998) . These biological activities of p53 have been tightly linked to its ability to bind to specific DNA sequence and activate transcription (Hupp et al., 1992; Crook et al., 1994; Pietenpol et al, 1994) . p53 is divided both structurally and functionally into several domains, including the NH 2 -terminal acidic transactivation domain, the hydrophobic core sequence-specific DNA-binding domain, and the COOH-terminal oligomerization domain. Vast majority of p53 mutations are detected within the highly conserved sequence-specific DNA-binding region, and abrogate its DNA-binding activity to result in the deregulated cell growth and/or the resistance to apoptosis (Hollstein et al., 1991; Levine et al., 1994; Prives and Hall, 1999) . Accumulating evidence suggests that the latent form of p53 is converted to the active form for its DNA-binding by various modifications of its extreme COOH-terminal region. The direct post-translational phosphorylation, glycosylation, or acetylation of this region enhanced its sequence-specific DNA-binding activity (Hupp et al., 1992; Takenaka et al., 1995; Wang and Prives, 1995; Gu and Roeder, 1997; Shaw et al., 1996) . In addition, physical interaction of , with the COOH-terminal region of p53 also stimulated its DNA-binding activity (Jayaraman et al., 1997; Waterman et al., 1998) .
p73 is a newly discovered p53-related gene (Kaghad et al., 1997) . p73 encodes a nuclear transcription factor which binds to the canonical p53-recognition sites and activates transcription from various p53-responsive promoters (Jost et al., 1997; Kaghad et al., 1997; Zhu et al., 1998; Di Como et al., 1999; Fang et al., 1999; Steegenga et al., 1999) . Ectopic overexpression of p73 induced cell cycle arrest and/or apoptosis in cells irrespective of their p53 status (Jost et al., 1997; Kaghad et al., 1997) . Unlike p53, p73 is rarely mutated in human tumors (Ikawa et al., 1999) , and p73-deficient mice did not develop any spontaneous tumors . Additionally, enforced expression of cellular and viral oncogenes such as E2F-1, c-myc, and E1A stimulated the expression of p73 Lissy et al., 2000; Stiewe and Putzer, 2000; Zaika et al., 2001) , and p73 mRNA was overexpressed in several types of tumor cells (Zaika et al., 1999; Chen et al., 2000) . Thus, the physiological contribution of p73 in tumorigenesis remains unknown despite the structural and the functional similarities between p73 and p53. In contrast to p53-deficient mice, p73-null mice exhibited neurological, pheromonal, and inflammatory abnormalities . Recently, it has been shown that the endogenous level of p73 expression was increased during muscle and neuronal differentiation (Fontemaggi et al., 2001) , and overexpression of p73 but not p53 stimulated neuroblastoma cell differentiation (De Laurenzi et al., 2000) .
Unlike p53, p73 encodes various isoforms (a, b, g, d , e, and z), arising from the alternative splicing events of the primary p73 mRNA (Kaghad et al., 1997; De Laurenzi et al., 1998 Ueda et al., 1999) . These isoforms with different COOH-terminal tails were expressed differentially among normal tissues and cell lines (De Laurenzi et al., 1998 Ueda et al., 1999) . Although physiological functions of those isoforms are still unknown, they have different transcriptional and biological properties (De Laurenzi et al., 1998; Zhu et al., 1998; Di Como et al., 1999; Ueda et al., 1999) . Recently, Yang et al. (2000) discovered the NH 2 -terminally truncated, transactivation-deficient p73 isoform (DNp73), which is generated from an alternative promoter located within the intron 3. DNp73 contains a dominant-negative activity against p73 as well as p53 (Pozniak et al., 2000) . Intriguingly, p73 directly bound to the p73-responsive element found in the DNp73 promoter region and induced the transcription of DNp73, suggesting that there exists the negative feedback regulation of p73 by its target DNp73 (Grob et al., 2001; Nakagawa et al., 2002) .
We and others demonstrated that the COOH-terminal truncation of p73a significantly enhanced its sequencespecific DNA binding as well as transactivation activities (Ozaki et al., 1999; Ueda et al., 1999) , suggesting that the sequence-specific transcriptional activity of p73 is negatively regulated by its own COOH-terminal domain. In the present study, we have employed the yeast-based two-hybrid screen to isolate and characterize the cellular protein(s), which can interact with the extreme COOH-terminal region of p73a and modulate its activity. From the screening of the cDNA libraries derived from human fetal brain and 293 cells, we have identified the receptor for activated C kinase (RACK1) as a protein binding at the p73a-COOH-terminal region. Transient transfection experiments in p53-null human osteosarcoma SAOS-2 cells revealed that RACK1 efficiently repressed the p73a-mediated transcriptional activation as well as apoptosis. On the other hand, the RACK1-mediated inhibition of p73a was not observed in p53-null human lung adenocarcinoma H1299 cells, which express functional pRB. Furthermore, we found that pRB inhibited the RACK1-mediated repression of p73a through the interaction with RACK1.
Results

Two-hybrid screening
The yeast two-hybrid protein interaction screening was carried out to isolate cellular protein(s) that could bind to the extreme COOH-terminal region of p73a. The yeast strain CG1945 was simultaneously transformed with a 'bait' plasmid containing the cDNA encoding the p73a COOH-terminal region (amino-acid residues 551-636) and a 293 or a human fetal brain cDNA library. Transformants (approximately 2 Â 10 6 ) were subjected to dual selection (HIS + , LacZ + ). We have obtained 14 and 10 independent positive clones from 293 and human fetal brain cDNA libraries, respectively, and their nucleotide sequences were determined. Of interest, out of 24 positive clones, 12 encoded the overlapping COOH-terminal regions of RACK1 (Figure 1a ). RACK1 is a Trp-Asp (WD) repeat protein that has previously been shown to interact with activated protein kinase C (Ron et al., 1994; . Since all of 12 RACK1 cDNA clones possessed the WD-6 and WD-7 domains, it was suggested that the COOH-terminal WD repeats were necessary for the interaction with the extreme COOH-terminal region of p73a.
Specific interaction of RACK1 and p73a in vitro
To further confirm the protein-protein interaction of RACK1 with p73a, in vitro binding assays were performed. We constructed a glutathione S-transferase (GST) and GST-RACK1(171-317) fusion protein ( Figure 1b) . The in vitro translated and [ 35 S]methioninelabeled p73a or p53 was incubated with GST, or GST-RACK1(171-317) immobilized onto glutathioneSepharose beads. The beads were washed with binding buffer three times, and GST or GST-RACK1(171-317) bound proteins were eluted with SDS sample buffer. Following 10% SDS-polyacrylamide gel electrophoresis, the bound proteins were analysed by autoradiography. As shown in Figure 1c , p73a bound to GST-RACK1(171-317) but not to GST, whereas p53 did not bind to . In our experimental conditions, p73b and p73a(1-548), which lacked the extreme COOH-terminal portion of p73a, did not bind to GST-RACK1(171-317) (data not shown). These results were consistent with the findings in the yeast twohybrid interaction assays, and suggest that RACK1 interacts specifically with p73a but not with p73b or p53.
Coimmunoprecipitation of RACK1 with p73a
To examine whether RACK1 could interact with p73a in cells, COS7 cells were transiently transfected with the expression plasmid encoding FLAG-RACK1, which was designed to express full-length RACK1 protein tagged with FLAG on its NH 2 -terminus, together with the expression plasmid for HA-tagged p73a. Detergent lysates of transfected cells were immunoprecipitated with a monoclonal anti-FLAG or a polyclonal anti-p73a antibody, and the immunoprecipitated proteins were analysed by Western blotting using a monoclonal antip73a or the anti-FLAG antibody, respectively. As shown in Figure 2a , RACK1 coprecipitated with p73a. Immunoblotting of whole cell lysates showed approximately equal expression of HA-p73a and FLAG-RACK1 in the transfections (Figure 2a , lower panels). These results confirm the interaction between RACK1 and p73a. To examine whether RACK1 could colocalize with p73a in mammalian cultured cells, we performed double immunofluorescence staining. COS7 cells expressing FLAG-RACK1 and HA-p73a were incubated with the anti-FLAG and the anti-HA antibodies followed by the rhodamine-conjugated anti-mouse IgG and the FITC-conjugated anti-rabbit IgG. As shown in Figure 2b , the localization of the ectopically overexpressed RACK1 and p73a overlapped in the cell nucleus.
To map the region of p73a that interacts with RACK1 in cells, COS7 cells were transiently transfected with the expression plasmid for FLAG-RACK1 together with the expression plasmid for HA-p73a, p73a(1-427), p73a(1-548), or p73b. As expected, RACK1 failed to coprecipitate with those p73a COOH-terminal deletion mutants or with p73b ( Figure   2c and d), suggesting that the extreme COOH-terminal region of p73a is sufficient for the interaction with RACK1. We also tested RACK1 for its ability to bind to p53 by coimmunoprecipitation experiments. p53-deficient H1299 cells were transiently transfected with the expression plasmid for p53, FLAG-RACK1, or p53 and FLAG-RACK1. In agreement with the in vitro binding assays, RACK1 did not coprecipitate with p53 ( Figure 2e ). These results suggest that RACK1 is associated with p73a but not with p53 in cells.
RACK1 inhibits the p73a-dependent transcription
To examine whether RACK1 could affect the p73a-dependent transcriptional activation, SAOS-2 cells were Functional interaction between p73, RACK1, and pRB T Ozaki et al Figure 2 Interaction between RACK1 and p73a in cells. (a) COS7 cells were transiently transfected with the expression plasmids encoding HA-p73a, FLAG-RACK1, or HA-p73a and FLAG-RACK1 as indicated at the bottom. At 48 h after transfection, whole-cell lysates were subjected to immunoprecipitation (IP) using the anti-FLAG (M2), or the anti-p73a (C-17) antibody. Immunoprecipitates were analysed by immunoblotting (IB) with the anti-p73a (Ab-1), or the anti-FLAG antibody (upper panels). Lower panels show the Western blotting with the anti-HA (12CA5), or the anti-FLAG antibody to monitor the expression level of the transfected constructs. (b) COS7 cells were transiently transfected with the expression plasmids for HA-p73a and FLAG-RACK1. After fixation and permeabilization, the cells were stained with the anti-HA and the anti-FLAG antibodies followed by FITC-conjugated anti-rabbit IgG (green) and rhodamine-conjugated anti-mouse IgG (red). Nuclear colocalization of p73a and RACK1 is indicated by the yellow. (c) Whole-cell lysates from COS7 cells transiently transfected with the expression plasmids for FLAG-RACK1 and HA-p73a, HA-p73a(1-427), or HA-p73a(1-548) were immunoprecipitated with the anti-p73 antibody (Ab-4), and analysed by immunoblotting with the anti-FLAG antibody (top panel). Whole-cell lysates were monitored on Western blot for expression of these components (middle and bottom panels). (d) Whole-cell lysates from COS7 cells expressing either FLAG-RACK1 and HA-p73a or FLAG-RACK1 and HA-p73b were immunoprecipitated with the anti-p73 (Ab-4) antibody, and immunoblotted with the anti-FLAG antibody (top panel). Whole-cell lysates were monitored on Western blot for expression of HA-p73a and HA-p73b, or FLAG-RACK1 using the anti-p73 (middle panel), or the anti-FLAG (bottom panel) antibody, respectively. (e) H1299 cells were transiently transfected with the indicated expression plasmids. After 48 h, whole-cell lysates were immunoprecipitated with the anti-p53 antibodies (DO-1 and PAb1801), and subjected to the immunoblot analysis using the anti-FLAG antibody (top panel). The expression of FLAG-RACK1 and p53 was checked by immunoblotting with the anti-FLAG and the anti-p53 (DO-1) antibodies, respectively (middle and bottom panels, respectively)
Functional interaction between p73, RACK1, and pRB T Ozaki et al transiently cotransfected with the p73a expression plasmid together with a luciferase reporter plasmid placed under the control of the p53/p73-responsive element from p21, MDM2, or Bax promoter in the presence or the absence of the expression plasmid for RACK1. As shown in Figure 3 , RACK1 alone did not induce the luciferase reporter activation, and coexpression of RACK1 with p73a resulted in the inhibition of the p21, MDM2, or Bax-luciferase activity induced by p73a. In contrast, RACK1 failed to affect the p53-mediated transcriptional activation, as expected. Similarly, RACK1 had no significant effect on the p73b-mediated transcriptional activation (data not shown). To verify the role of the extreme COOHterminal portion of p73a in the RACK1-mediated inhibition, similar luciferase reporter assays were performed using the COOH-terminal deletion mutants of p73a, p73a(1-427), and p73a(1-548). In agreement with the previous observations (Ozaki et al., 1999) , the COOH-terminal deletions markedly enhanced the transcriptional activity of p73a ( Figure 4 ). When those p73a deletion mutants were coexpressed with RACK1, their ability to drive transcription from MDM2 or Bax promoter was not affected in the presence of RACK1 (Figure 4 ). Thus, these results suggest that the transactivation function of p73a is impeded through the physical interaction with RACK1.
RACK1 inhibits the p73a-mediated apoptosis
In view of the ability of RACK1 to interact with p73a as well as to reduce its transactivation function, we next determined whether RACK1 could inhibit the p73a-mediated apoptosis. SAOS-2 cells were transiently transfected with the expression plasmid for HA-p73a or p53 in the presence or the absence of the increasing amounts of the expression plasmid for FLAG-RACK1. These expression constructs were cotransfected with a bgalactosidase expression plasmid (pCH110) to identify transfected cells. The number of b-galactosidase-positive cells were scored 48 h after the transfection, and the levels of ectopically expressed proteins were analysed by Western blotting ( Figure 5 ). As shown in Figure 5a , c, ectopic overexpression of p53 or p73a resulted in the significant decrease in the number of b-galactosidasepositive cells as compared to that transfected with the empty plasmid alone, whereas the number of bgalactosidase-positive cells expressing exogenous RACK1 was similar to that observed in the back bone plasmid-transfected cells. As described previously, the Functional interaction between p73, RACK1, and pRB T Ozaki et al suppression of SAOS-2 cell growth by p53 or p73 was thought to be due largely to apoptosis (Pietenpol et al., 1994; Jost et al., 1997) . When p73a was coexpressed with RACK1, the number of b-galactosidase-positive cells was increased in a dose-dependent manner, as compared to that transfected with the expression plasmid for p73a alone (Figure 5a ). On the other hand, coexpression of RACK1 had no significant effect on the p53-dependent decrease in the number of b-galactosidase-positive cells (Figure 5c ).
pRB interacts with RACK1
We then asked whether RACK1-mediated inhibition of the transcriptional activity of p73a could also be observed in human large-cell lung carcinoma H1299 cells, which lacked the endogenous expression of p53.
To this end, we performed transient transfections with
HA-p73a and the increasing amounts of FLAG-RACK1 expression plasmids concomitantly with the p53/p73 reporter gene construct (p21, MDM2 or Bax) in Figure 4 The extreme COOH-terminal region is required for the RACK1-dependent inhibition of p73a. SAOS-2 cells were transiently transfected with 100 ng of the expression plasmid encoding p73a, p73a(1-427), or p73a(1-548) in the presence or the absence of the expression plasmid for RACK1 (800 ng) together with the luciferase reporter construct (1 mg) driven by the p53/p73-responsive element derived from MDM2 (a) or Bax (b) promoter and the Renilla luciferase plasmid (50 ng). All transfections were performed in triplicate. At 48 h following transfection, cells were harvested for luciferase assay. The indicated values are the average of three independent experiments expressed as the fold activation for each reporter plasmid with the indicated effector plasmids as compared with pcDNA3 alone (Figure 6a -c). As described previously (Zaika et al., 2001) , H1299 cells express functional pRB, whereas SAOS-2 cells do not (Figure 6d ). To determine whether pRB could affect the physical interaction between p73a and RACK1, COS7 cells were cotransfected with HAp73a and FLAG-RACK1 together with the increasing amounts of the pRB expression plasmid encoding the NH 2 -terminally truncated pRB (amino acids 301-928), which retained a biological function of pRB (Qin et al., Figure 6 Physical interaction between RACK1 and pRB. p53-deficient human lung carcinoma H1299 cells were transiently transfected with 100 ng of the expression plasmid encoding p73a in the presence or the absence of the increasing amounts of the expression plasmid for RACK1 (100, 200, 400, or 800 ng) together with the luciferase reporter construct (1 mg) driven by the p53/p73-responsive element derived from p21 (a), MDM2 (b), or Bax (c) promoter, and the Renilla luciferase plasmid (50 ng). All transfections were performed in triplicate. At 48 h after the transfection, cells were harvested for luciferase assay. (d) Whole-cell lysates derived from SAOS-2 or H1299 cells were analysed in Western blots with antibodies against pRB (C-15), p53 (DO-1), RACK1 (clone 20), or actin (20-33). (e) COS7 cells were transiently transfected with the expression plasmids for HA-p73a (1 mg) and FLAG-RACK1 (1 mg) in the presence or the absence of the increasing amounts of the pRB(301-928) expression plasmid (1 or 2 mg). Whole-cell lysates were immunoprecipitated with the anti-p73 antibody, followed by immunoblotting with the anti-FLAG (top panel) or the anti-HA (2nd panel) antibody. Whole-cell lysates were immunoblotted with the anti-FLAG antibody (third panel) or the antibody specific to pRB (fourth panel). The anti-FLAG blot was reprobed with the anti-pRB antibody (fifth panel). (f) Whole-cell lysates derived from COS7 cells transfected with the indicated expression plasmids were immunoprecipitated with the anti-FLAG or the anti-pRB antibody, and then immunoprecipitated proteins were subjected to Western blot using the anti-pRB (top panel), or the anti-FLAG (second panel) antibody, respectively. Whole-cell lysates were analysed by Western blotting using the anti-pRB (third panel), or the anti-FLAG (fourth panel) antibody
Functional interaction between p73, RACK1, and pRB T Ozaki et al 1992). Whole-cell lysates were immunoprecipitated with the anti-p73 antibody, and precipitated proteins were analysed by immunoblotting with the anti-FLAG antibody. As shown in Figure 6e , coexpression of pRB(301-928) did not affect the complex formation between p73a and RACK1. Intriguingly, when the anti-FLAG blot was reprobed with the anti-pRB antibody, coprecipitated pRB(301-928) was detected in the anti-p73 immunoprecipitates (Figure 6e , fifth panel), raising a possibility that pRB could be associated with p73a and/ or RACK1 in mammalian cells. To examine whether pRB could interact with RACK1, we performed coprecipitation experiments using COS7 cells transfected with FLAG-RACK1 and pRB(301-928) expression plasmids. As shown in Figure 6f , pRB(301-928) clearly immunoprecipitated with FLAG-RACK1. The reverse experiments, in which the anti-pRB antibody was used in the immunoprecipitation followed by immunoblot analysis with the anti-FLAG antibody, revealed that FLAG-RACK1 was detected in the antipRB immunoprecipitates. Taken together, these results raise a possibility that pRB abrogates the inhibitory effect of RACK1 on p73a through the interaction with RACK1.
pRB antagonizes the RACK1-mediated inhibition of p73a
To examine whether pRB could block the RACK1-mediated inhibition of the transcriptional activity of p73a, we performed the transient transfections with p73a and RACK1 expression plasmids along with the p53/p73-responsive p21 or Bax luciferase reporter construct in the presence or the absence of the pRB(301-928) expression plasmid. As shown in Figure 7 , the reduced level of the p73a-mediated luciferase activity caused by exogenous RACK1 was recovered by coexpression of pRB(301-928). Consistent with these observations, overexpression of pRB(301-928) enhanced the transcriptional activity of p73a in the absence of exogenous RACK1, raising a possibility that pRB(301-928) might inhibit the endogenous RACK1. Taken together, our results suggest that pRB blocks the RACK1-mediated inhibition of the transcriptional activity of p73a.
Discussion
The deletion of the COOH-terminal region of p73a enhances its sequence-specific transactivation ability, suggesting that, like p53, the COOH-terminal region of p73a has a negative regulatory property that modulates its transcriptional activity (Ozaki et al., 1999; Ueda et al., 1999) . However, the molecular basis of this negative regulatory mechanism has been largely unclear. In the present study, we have identified RACK1 as a suppressor of p73a. This RACK1-mediated inhibition is specific to p73a, but not to p53 or p73b, suggesting that the physical interaction is required for the inhibitory activity of RACK1. Furthermore, our data have demonstrated that pRB efficiently blocks the RACK1-dependent repression of p73a through the interaction with RACK1.
The importance of the COOH-terminal region of p53 family molecules has been insisted in many aspects of their functions. Strano et al. (2001) have reported that the Yes-associated protein (YAP) interacts with p73 but not with p53. This binding is mediated by the COOHterminal PPPPY motif (amino-acid residues 482-488) in p73 and the WW domain of YAP, and the overexpression of YAP enhances the p73a-dependent transcriptional activation in p53-deficient H1299 cells. We have also identified MM1, a nuclear c-myc-binding protein, as a p73a COOH-terminal region-binding protein . MM1 not only enhances the activity of p73a but also antagonizes the inhibitory effect of c-myc on p73a. In addition, Minty et al. (2000) have identified small ubiquitin-like modifier 1 (SUMO-1) as a p73-binding protein by the yeast twohybrid screen, and the COOH-terminal lysine (Lys-627) of p73a is covalently modified by SUMO-1. SUMO-1 interacts with p53, and the single lysine residue, which is localized in the extreme COOH-terminus of p53, is modified by SUMO-1 (Gostissa et al., 1999; Kwek et al., 2001; Rodriguez et al., 1999) . In contrast to the interaction between p73a and YAP or MM1, SUMO-1 modification does not affect the transcriptional activity of p73a (Minty et al., 2000) .
Our present results have shown that the overexpression of RACK1 in p53-and pRB-deficient SAOS-2 cells leads to the decrease of p73a-dependent transcriptional activity. This inhibition is dependent on the physical interaction between p73a and RACK1, because RACK1 overexpression does not influence the transcriptional activity of p53. As described previously (Ozaki et al., 1999) , the COOH-terminal truncation of p73a results in the enhancement of its transcriptional activity. This effect might be in part because of an inability of the COOH-terminal deletion mutants to bind to RACK1. It is worth noting that RACK1 consists of highly conserved seven repeating units of WD motifs, which may be involved in the protein-protein interaction (Ron et al., 1994; Springer, 1994) , raising a possibility that RACK1 acts as the adapter molecule between transcriptional repressor(s) and the COOH-terminal regulatory region of p73a. Alternatively, the association of RACK1 with the COOH-terminal region of p73a might alter the capacity of p73a to interact with cellular protein(s) with coactivator function. Sang et al. (2001) found that RACK1 bound to E1A and disrupted the interaction between E1A and a histone acetyltransferase (HAT) activity to protect cells from E1A-induced apoptosis. Our b-galactosidase assays showed that RACK1 at least in part inhibited the p73a-induced apoptosis. Recently, it has been reported that Cpc2, a yeast homolog of mammalian RACK1, has an important role for the cell cycle progression (Mcleod et al., 2000) . As described by Zeng et al. (2000) , p300/CBP with HAT activity interacts with the NH 2 -terminus of p73, and stimulates both the transactivation and the proapoptotic function of p73. In addition, MDM2 suppresses the p73 function by disrupting the interaction of p73 with p300/CBP (Zeng et al., 1999) . Although the precise molecular mechanism through which RACK1 inhibits the function of p73a is not known, it is possible that RACK1 might affect the functional interaction between p73a and cellular transcriptional coactivators with HAT activity such as p300/CBP. As described previously, RACK1 is reported to interact with the activated forms of PKCs and anchor them close to their physiological substrates (Ron et al., 1994 . The physical interaction between RACK1 and integrin b subunit or Src is dependent on the stimulation of cells with phorbol ester PMA (Liliental and Chang, 1998; Chang et al., 2001) , suggesting that PKC activation is required for the above interaction. On the other hand, the interaction of RACK1 with the common b-chain of the cytokine receptors, cAMPspecific phosphodiesterase isoform PDE4D5 or BZLF1 is constitutive and unaffected in the presence of PMA (Geijsen et al., 1999; Yarwood et al., 1999; Baumann et al., 2000) . Thus, RACK1 appears to be associated with cellular proteins in a manner dependent or independent on the PKC activation. Our coimmunoprecipitation experiments have revealed that the ability of RACK1 to bind to p73a is not affected by the treatment of COS7 or CHO cells with PMA (data not shown), suggesting that the binding is not dependent on the PKC activation.
Another issue to be addressed is that the inhibitory activity of RACK1 toward the p73a-dependent transactivation has not been detected in H1299 cells. In contrast to SAOS-2 cells, H1299 cells expressed functional pRB (Zaika et al., 2001) , indicating the presence of an additional pRB-dependent mechanism regulating the physical and/or functional interaction of p73a with RACK1. Our luciferase reporter assays demonstrated that the reduced p73a transcriptional activity caused by exogenously expressed RACK1 was significantly recovered by coexpression of pRB in SAOS-2 cells. We also found that pRB did not affect the physical interaction between p73a and RACK1, whereas RACK1 was detected in the anti-pRB immunoprecipitates, suggesting that pRB inactivated the function of RACK1 to inhibit the transcriptional activity of p73a through the direct interaction. Therefore, our findings suggest the existence of a functional link between p73, RACK1 and pRB. Taken together, the transcriptional activity of p73a may be negatively modulated by RACK1; however, the precise molecular mechanism of the pRBmediated inhibition of RACK1 to suppress the transcriptional activation of p73a remains to be elucidated. To further confirm the functional interaction among p73a, RACK1 and pRB, it is necessary to perform the siRNA-mediated inactivation of the endogenous pRB and/or RACK1 in H1299 cells.
Materials and methods
Cell culture and transient transfection
Human osteosarcoma SAOS-2 and COS7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Life Technologies, Inc., Grand Island, NY, USA) and penicillin (100 IU/ml)/streptomycin (100 mg/ml). Human lung adenocarcinoma H1299 cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS and antibiotic mixture. Cultures were maintained at 371C in a water-saturated atmosphere of 5% CO 2 in air. For a transient transfection experiment, COS7 or H1299 cells were transfected with the indicated expression plasmids by using FuGENE 6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's protocol. Transient transfection of SAOS-2 cells was performed by LipofectA-MINE Plus (Life Technologies, Inc.) in accordance with the manufacturer's recommendations.
Yeast two-hybrid screening
The yeast two-hybrid screening was carried out essentially as described previously . The COOHterminal region of p73a (amino-acid residues 551-636) was cloned in frame into pAS2-1 coding sequence to generate a 'bait' plasmid, pAS2-1/p73aCOOH. Screens were performed with a cDNA library derived from human fetal brain or 293 cells in the pACT yeast expression vector (Clontech Laboratories, Inc., Palo Alto, CA, USA). Both plasmids were introduced into the Saccharomyces cereviciae strain CG1945, and positive clones were initially selected for growth in the absence of histidine. Sequential qualitative b-galactosidase assay was performed to eliminate false positives according to the manufacturer's instructions (Clontech Laboratories, Inc.). The interacting cDNA clones were rescued from the selected yeast transformants. The nucleotide sequences of the positive cDNA clones were determined by the dideoxy terminator cycle Functional interaction between p73, RACK1, and pRB T Ozaki et al sequencing method using an automated Prism 377 DNA sequencer (Perkin-Elmer Life Sciences and Applied Biosystems, Foster City, CA, USA) and nucleotide sequence databases were searched for homologous sequences with BLAST program.
Generation of a bacterial expression construct
The cDNA clone encoding the COOH-terminal region of human RACK1 (K5; amino-acid residues 171-317) was digested with EcoRI and XhoI and subcloned into the identical restriction sites of the pGEX-4T1 (Amersham Pharmacia Biotech, Piscataway, NJ, USA) to create pGEX-RACK1(171-317). Cultures of E. coli DH5a harboring the pGEX-4T1 or pGEX-RACK1(171-317) were induced with 1 mm isopropylb-d-thiogalactopyranoside for 6 h at 371C. Cells were harvested by centrifugation at 4000 r.p.m. for 5 min at 41C and the bacterial pellet was resuspended in NETN buffer (50 mm Tris-HCl, pH 7.5, 150 mm NaCl, 0.1% Nonidet P-40 and 1 mm EDTA). After the brief sonication, the lysate was centrifuged at 12 000 r.p.m. for 30 min at 41C to remove insoluble materials. The cleared supernatant was incubated with 1/10th volume of preequilibrated glutathione-Sepharose beads (Amersham Pharmacia Biotech) for 30 min at 41C. GST fusion proteins bound to the beads were recovered with an elution buffer containing 5 mm glutathione and dialyzed against ice-cold phosphate-buffered saline (PBS).
In vitro interaction assay
Radiolabeled p73a or p53 was generated in vitro with [ 35 S]methionine using the quick coupled in vitro transcription and translation system (TNT) according to the procedure suggested by the manufacturer (Promega Corp., Madison, WI, USA). For the glutathione-Sepharose pull-down assays, radiolabeled p73a or p53 (10 ml of a 50 ml reaction) was mixed with the GST protein or GST fusion protein (1 mg) in 400 ml of NETN buffer containing 1 mm phenylmethylsulfonyl fluoride (PMSF). Following incubation in the presence of glutathioneSepharose beads for 2 h at 41C with gentle shaking, the beads were washed three times with the binding buffer. The bound proteins were then eluted by boiling in the SDS sample buffer (62.5 mm Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.1 M DTT, and 0.01% bromophenol blue) for 5 min and analysed on a 10% SDS-polyacrylamide gel. Following electrophoresis, the gel was destained, dried, and exposed to an X-ray film with an intensifying screen at À801C.
Generation of a cDNA encoding a FLAG-tagged RACK1
The full-length cDNA of human RACK1 was amplified from human fetal brain cDNA by polymerase chain reaction (PCR) using the following primers: sense, 5 0 -TCGCC GCGGCCGCGACTGAGCAGATGA-3 0 (the NotI recognition site is underlined); antisense, 5 0 -CATAGTCGAC-TAGCGTGTGCCAAT-3 0 (the SalI restriction site is underlined). The amplified cDNA was digested with NotI and SalI and subcloned into the NotI and XhoI restriction sites of the pcDNA3-FLAG (kindly provided by Dr Toshiharu Suzuki, University of Tokyo, Tokyo, Japan) to give pcDNA3-FLAG-RACK1.
Immunofluorescence staining and confocal microscopy
Transfected cells were fixed in 3.7% formaldehyde for 30 min at room temperature, permeabilized with 0.2% Triton X-100 for 5 min at room temperature and blocked for 1 h in 1 Â PBS containing 3% bovine serum albumin (BSA). Cells were then prepared for double-immunofluorescence staining and analysed by confocal microscopy. HA-p73a was stained using a polyclonal anti-HA antibody (diluted 1 : 500; Medical and Biological Laboratories, Nagoya, Japan) and the corresponding anti-rabbit IgG antibody conjugated to FITC (Life Technologies, Inc.). FLAG-RACK1 was detected with a monoclonal anti-FLAG M2 antibody (diluted 1 : 50; Sigma, St. Louis, MO, USA) and the corresponding anti-mouse IgG antibody conjugated to rhodamine.
Immunoblotting
Cells were lysed in the lysis buffer (25 mm Tris-HCl, pH 7.5, 137 mm NaCl, 2.7 mm KCl, 1% Triton X-100, and 1 mm PMSF) (Baumann et al., 2000) . The extracts were sonicated for 10 s and centrifuged at 15 000 r.p.m. for 10 min to remove insoluble materials. The protein concentrations were determined by the Bradford protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Protein samples were boiled in the SDSsample buffer, subjected to 10% SDS-polyacrylamide gel electrophoresis and then electrotransferred onto a nitrocellulose membrane. The blot was then probed with the anti-FLAG (Sigma), the anti-HA (12CA5, Roche Molecular Biochemicals), the anti-p53 (DO-1, Oncogene Research Products, Cambridge, MA, USA), the anti-p73 (Ab-4, NeoMarkers, Inc., Fremont, CA, USA), the anti-pRB (C-15, Santa Cruz Biotechnology, Santa Cruz, CA, USA), the anti-RACK1 (clone 20, Transduction Laboratories, Lexington, KY, USA) or the anti-actin (20-33, Sigma) antibody, followed by an incubation with the appropriate horseradish peroxidase-conjugated secondary antibodies (diluted 1 : 2000; Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Protein bands were visualized by enhanced chemiluminescence (ECL) according to the manufacturer's instructions (Amersham Pharmacia Biotech).
Coimmunoprecipitation
At 48 h post-transfection, cells were lysed in 400 ml of the lysis buffer (25 mm Tris-HCl, pH 7.5, 137 mm NaCl, 2.7 mm KCl, 1% Triton X-100, and 1 mm PMSF). The soluble supernatants were mixed with the anti-p73a (C-17, Santa Cruz Biotechnology) or the anti-FLAG antibody, and incubated for 2 h at 41C. Protein G-Sepharose beads were then added and incubated for 1 h at 41C. The samples were washed with the lysis buffer three times and the bound proteins were eluted by boiling in the SDS-sample buffer. Proteins were analysed by 10% SDSpolyacrylamide gel electrophoresis, semidry blotted onto a nitrocellulose membrane and probed with the anti-FLAG or the anti-p73a (Ab-1, Oncogene Research Products). Immunocomplexes were detected by ECL (Amersham Pharmacia Biotech).
Luciferase assays
SAOS-2 cells were plated for transfection at a density of 5 Â 10 4 cells/well in a 12-well tissue culture dish for 24 h. Cells were cotransfected with 1 mg of the indicated p53/p73-responsive reporter plasmid (p21, MDM2, or Bax), 50 ng of pRL-TK Renilla luciferase cDNA, and 0.1 mg of the indicated expression plasmid (p53, p73a, p73a(1-427), p73a(1-548), or p73b) in the presence or absence of the expression plasmid for FLAG-tagged RACK1 (0.8 mg). The total amount of DNA was kept constant (2.05 mg) with pcDNA3 (Invitrogen, Carlsbad, CA, USA). At 48 h post-transfection, cells were lysed and luciferase activity was measured by using the dualluciferase reporter assay system (Promega, Corp.) according to the manufacturer's instructions. The transfection efficiency was standardized against Renilla luciferase. The experiments were repeated three times.
b-galactosidase assays SAOS-2 cells were plated on a 12-well tissue culture dish (5 Â 10 4 cells/well) and transiently transfected with 125 ng of the reporter plasmid pCH110 (Amersham Pharmacia Biotech), which encodes E. coli b-galactosidase, plus 25 ng of the expression plasmid for HA-p73a or p53 in the presence or the absence of the increasing amounts of the expression plasmid encoding FLAG-RACK1 by the LipofectAMINE procedure. The total amount of transfected plasmid DNA was kept constant (500 ng/transfection) by adding pcDNA3. At 48 h post-transfection, cells were fixed with 0.25% glutaraldehyde in PBS, the transfected cells were detected by staining with 5-bromo-4-chloro-3-indolyl b-d-galactopyranoside (Xgal), and the number of b-galactosidase-expressing cells was scored. The experiments were repeated three times.
